Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience

Biometric Monitoring Technologies (BioMeTs) are becoming increasingly common to aid data collection in clinical trials and practice. The state of BioMeTs, and associated digitally measured biomarkers, is highly reminiscent of the field of laboratory biomarkers two decades ago. In this review, we have summarized and leveraged historical perspectives, and lessons learned from laboratory biomarkers as they apply to BioMeTs. Both categories share common features, including goals and roles in biomedical research, definitions, and many elements of the biomarker qualification framework. They can also be classified based on the underlying technology, each with distinct features and performance characteristics, which require bench and human experimentation testing phases. In contrast to laboratory biomarkers, digitally measured biomarkers require prospective data collection for purposes of analytical validation in human subjects, lack well-established and widely accepted performance characteristics, require human factor testing and, for many applications, access to raw (sample-level) data. Novel methods to handle large volumes of data, as well as security and data rights requirements add to the complexity of this emerging field. Our review highlights the need for a common framework with appropriate vocabulary and standardized approaches to evaluate digitally measured biomarkers, including defining performance characteristics and acceptance criteria. Additionally, the need for human factor testing drives early patient engagement during technology development. Finally, the use of BioMeTs requires a relatively high degree of technology literacy among both study participants and healthcare professionals. Transparency of data generation and the need for novel analytical and statistical tools creates opportunities for precompetitive collaborations

Microbially induced biobeneficiation of hematite

Selective separation of alumina, silica, calcite and apatite from hematite was achieved through microbiologically induced flotation and flocculation in presence of bacteria (B.subtilis) and that of hematite from apatite after interaction with yeast (Saccharomyces cerevisiae). Bacterial and yeast metabolites containing extracellular proteins were characterized from mineral-grown cell free extract. Bacteria and yeast can adhere to mineral surfaces and influence subsequent separation of the minerals. Bacteria functioned as a stronger depressant for hematite, while yeast cells depressed apatite at neutral pH. Selective affinity of the bacterial and yeast cells towards the mineral surface was observed through adsorption studies. Extracellular proteins (EP) were isolated from B.subtilis and yeast. The protein profile of the EP of bacterial and yeast cells grown in presence and absence of minerals was studied. This study has demonstrated the utility and amenability of microbially-induced mineral beneficiation of iron ores through bacterial and yeast cells and their metabolic by products

Microbially-induced pyrite removal from galena using Bacillus subtilis

Cells and metabolic products of Bacillus subtilis were used in microbially-induced flocculation and flotation to separate pyrite from galena. Enhanced selective affinity of bacterial cells towards pyrite was observed when compared to galena through adsorption studies. Both extracellular (EP) and intracellular (IP) bacterial proteins were isolated from B. subtilis before and after interaction with the minerals and their profiles established through SDS-PAGE. Protein fractions exhibited significant surface affinity towards galena when compared to pyrite. Presence of galena during bacterial growth promoted increased generation of extracellular proteins, while that of pyrite resulted in enhanced production of exopolysaccharides. Galena surfaces were rendered hydrophobic after bacterial interaction. © 2013 Elsevier B.V